Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer

被引:75
作者
Maruyama-Tabata, H
Harada, Y
Matsumura, T
Satoh, E
Cui, F
Iwai, M
Kita, M
Hibi, S
Imanishi, J
Sawada, T
Mazda, O [1 ]
机构
[1] Kyoto Prefectural Univ Med, Dept Microbiol, Kyoto 6028566, Japan
[2] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 6028566, Japan
[3] Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6028566, Japan
关键词
Epstein-Barr virus-based plasmid vector; episomal vector; polyamidoamine dendrimer; gene therapy; herpes simplex virus thymidine kinase; Ewing's sarcoma;
D O I
10.1038/sj.gt.3301044
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study demonstrates in vivo effectiveness of a nonviral vector system, Epstein-Barr virus (EBV)-based plasmid vector coupled with polyamidoamine (PAMAM) dendrimer (EBV/polyplex), in suicide gene therapy of cancer. The EBV-based vector is a plasmid vector containing EBV nuclear antigen I (EBNA1) gene and oriP from EBV genome. HSV1 tk gene was transferred into Ewing's sarcoma cell lines, A4573 and KP-EWS-YI, by using an EBV-based plasmid vector pSES.Tk, or a conventional plasmid vector, pS.Tk. Cells transfected with pSES. Tk/dendrimer showed approximately 100 times lower ID50 to ganciclovir (GCV) compared with those transfected with pS.Tk/dendrimer. Intratumoral injection of pSES.Tk/dendrimer but not pS.Tk/dendrimer drastically suppressed the growth of tumors which had generated from A4573 or Huh7 hepatocellular carcinoma (HCC) cells inoculated into severe combined immunodeficiency (SCID) mice. The treatment with pSES.Tk/dendrimer also resulted in significant prolongation of survival of the mice implanted with A4573. These results suggest that the EBV/polyplex system could be useful for in vivo suicide gene therapy of cancer.
引用
收藏
页码:53 / 60
页数:8
相关论文
共 25 条
[1]   EWING SARCOMA - EXVIVO SENSITIVITY TOWARDS NATURAL AND LYMPHOKINE-ACTIVATED KILLING [J].
ATZPODIEN, J ;
GULATI, SC ;
SHIMAZAKI, C ;
BUHRER, C ;
OZ, S ;
KWON, JH ;
KOLITZ, JE ;
CLARKSON, BD .
ONCOLOGY, 1988, 45 (06) :437-443
[2]  
BIELINSKA AU, 1996, NUCLEIC ACIDS RES, V54, P2176
[3]   A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers [J].
Evans, TJ ;
Brooks, L ;
Farrell, PJ .
GENE THERAPY, 1997, 4 (03) :264-267
[4]   CATIONIC LIPOSOME-MEDIATED TRANSFECTION [J].
FELGNER, PL ;
RINGOLD, GM .
NATURE, 1989, 337 (6205) :387-388
[5]  
FREEMAN SM, 1993, CANCER RES, V53, P5274
[6]  
HARADA Y, IN PRESS CANC GENE T
[7]   Use of EBV-based vector HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms [J].
Hirai, H ;
Satoh, E ;
Osawa, M ;
Inaba, T ;
Shimazaki, C ;
Kinoshita, S ;
Nakagawa, M ;
Mazda, O ;
Imanishi, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 241 (01) :112-118
[8]  
IZUQUIERDO M, 1996, GENE THER, V3, P491
[9]   Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia [J].
Judde, JG ;
Spangler, G ;
Magrath, I ;
Bhatia, K .
HUMAN GENE THERAPY, 1996, 7 (05) :647-653
[10]   Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: Comparison of two different Epstein-Barr virus-based vectors [J].
Kenney, S ;
Ge, JQ ;
Westphal, EM ;
Olsen, J .
HUMAN GENE THERAPY, 1998, 9 (08) :1131-1141